Microbot Medical Inc. · NASDAQ:MBOT
Microbot Medical — Investor Presentation (September 2024)
25 slides from Microbot Medical's investor presentation, Sep 11, 2024
Slide 1: Microbot Medical: Access-Ability for All
micrdbot ica ACCESS-ABILITY FOR ALL”
Slide 2: Disclaimers
DISCLAIMERS This presentation (together with any oral statements made in connection herewith, the “Presentation”), is provided for informational purposes only and has been prepared to assist interested parties in evaluating Microbot Medical inc. (“Microbot”) and for no other purpose. This Presentati
Slide 3: RAS Market Is Big and Growing
RAS MARKET IS BIG AND GROWING... Robotic Assisted Surgery Market Size, Global 2019-2030 $18 CAGR 2024-30: 6% read $16 guar a CAGR 2019-23: ane $29 & 12% sig str $8 g soo 5197 . & si0 on g $8.3 ms $8 $72 $7.4 7 $5.7 86 + $52 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030
Slide 4: RAS Companies, excluding China, and Chinese RAS Companies
RAS Companies, excluding China (n=t31) Chinese RAS Companies (n=57) g 00 iallec 9 Gor = Of scons Aire @ oot] Bes As ig ls Bas QD SEs esi) cummins pao) Bar = 6.02 mee HuRWA BER, fg) Ribones (OH unin mas antin fie! Simon cr a Neues fa] Ope —t aren, Be 4 i qiey COME (a esse © felon Mana Gan: NOT “ Medt
Slide 5: Robotic surgery landscape by specialty and FDA status
Laproscopy INTUITIVE) S2N5U5 FDA Clearance/ Approval FDA Clearance/ Approval ‘Source: FSI, Robotic Assisted Sugary Landscape, 2024 KTORmed Endoluminal INTUITIVE Johnson&Johnson /—UMAN TENSIONS Soft Tissue e RTE ACCURAY Q (PROCEPT} No NDR Gone Pertint™ : Ove: (NSGATECIRENTSHAWE] Microsurgery R Q GLEN
Slide 6: Total Addressable Market (USA)
TOTAL ADDRESSABLE MARKET (USA) * 6 + + + Bronchoscopy Knee Replacement Endovascular Laproscopy ~0.15M-0.2M ~1M ~5M ~6M Procedures / Year Procedures / Year Procedures / Year Procedures / Year
Slide 7: USA Endovascular Market
USA ENDOVASCULAR MARKET | USE owas = z ae | Peripheral =
Slide 8: Attractive Market
ATTRACTIVE MARKET Over $33.5 billion spent annually in the US on endovascular procedures. * Coronary: $17.7 billion, Neuro: $1.3 billion, Peripheral: $14.5 billion + Attractive reimbursement Peripheral Angiogr Structural Heart Neuro TAE/Thrombo Neuro Angi 33,528,111,300
Slide 9: Initial Target Therapies
INITIAL TARGET THERAPIES * Peripheral Vascular + Embolotherapy + Interventional Oncology + MSK + Others Liver Gl (metastasis) (stomach, hemorrhoids) Vascular malformation Kidney (metastasis) Prostate (Co) Uterine (fibroids) Msk
Slide 10: Time To Treatment
Time To Treatment (TTT, e.g. “Time Is Brain”) Radiation Exposure Pinsee Stall (ergonomics) = Atthe site = Due to the cumulative impact of of interventional radiolog radiation exposure during their career, experience lower back pain or neck HCP: imes more likely to pain develop cancer and 6 times mor
Slide 11: Supported by Interventionalists
SUPPORTED BY INTERVENTIONALISTS Do you anticipate that you will begin using a robotic-assisted vascular intervention system in the future? NO YES Ido not expect Within to personally use them leyear YES YES in 3+ years Within >1-3 years 1N=200 interventionalists, data on fle
Slide 12: Of Procedures Done Robotically
of 1% OF PROCEDURES DONE ROBOTICALLY' DDecuces from Public Records
Slide 13: Slide 13
Slide 14: Multiple Barriers Leading to Low Penetration
MULTIPLE BARRIERS LEADING TO LOW PENETRATION gal € fs Special training, ) long learning curve Extended Large set-up time footprint = FRx. = Uf Capital Dedicated expense infrastructure Cumbersome and expensive disposables
Slide 15: Multiple Barriers Leading to Low Penetration
MULTIPLE BARRIERS LEADING TO LOW PENETRATION
Slide 16: Slide 16
Slide 17: Eliminating Barriers, Allowing Access
ELIMINATING BARRIERS, ALLOWING ACCESS <a a a 2
Slide 18: Eliminating Barriers, Allowing Access
ELIMINATING BARRIERS, ALLOWING ACCESS Disposable + No capital expense + Increases procedure efficiency Small Footprint + Compact & Light + No dedicated infrastructure Mobile + Utilized in multiple sites of service “When operating seated away from radiation source im Remote Reduce exposure to radiati
Slide 19: Slide 19
Slide 20: Redefining Robotics Business Model
REDEFINING ROBOTICS BUSINESS MODEL Cc v Disposable No upfront capital expense Recurring revenue Capital Simpler & faster buying process Leverage department OPEX Not require special infrastructures Fits in any set up (OBL, ASC) Multiple-room activation Service Eliminate extensive expense to hire & su
Slide 21: Regulatory Status
REGULATORY STATUS CERTIFIED
Slide 22: Road to Commercialization
ROAD TO COMMERCIALIZATION IDE approval to commence pivotal human clinical trial for LIBERTY® Robotic System IP Portfolio Expand and protect the ‘Company's global IP) portfolio in global jurisdictions, which creates significant barriers to entry Trials Initiate pivotal human clinical trial for LIBERT
Slide 23: Access-Ability for All
ACCESS-ABILITY FOR ALL™
Slide 24: Endovascular market is very large (~5M procedures in the USA alone)
Endovascular market is very large (~5M procedures in the USA alone) Many endovascular procedures are life saving procedures (e.g. stroke) Clear unmet needs effect all stakeholders Attractive reimbursement Limited players with no differentiation and same business model
Slide 25: Microbot Medical: Access-Ability for All
micrdbot ica ACCESS-ABILITY FOR ALL”
Microbot Medical — Investor Presentation (September 2024) on 6ix